epocrates
Drug Updates: Week of March 2, 2026
Here's a quick roundup of last week’s new drugs and updates in epocrates.
New Brand Drugs
- Indications: mild-moderate atopic dermatitis in adult and pediatric patients ≥2 years old
- Formulation: topical ointment
- Read more: FDA approves Adquey for mild-to-moderate atopic dermatitis
- Indications: arginase 1 deficiency in adult and pediatric patients ≥2 years old
- Formulation: subcutaneous or intravenous injection
- Read more: FDA grants accelerated approval to Loargys for arginase I deficiency
Quiofic (folic acid [vitamin B9])
- Indications: 1) folate deficiency-associated megaloblastic anemia in adult and pediatric patients; and 2) dietary supplementation in adult and pediatric patients
- Formulation: oral solution
New and Expanded Indications
- New: 1) retinal vein occlusion-associated macular edema; 2) diabetic macular edema; and 3) diabetic retinopathy
- Existing: neovascular age-related macular degeneration
- New: 1) heterozygous familial hypercholesterolemia in pediatric patients ≥12 years old; and 2) homozygous familial hypercholesterolemia in pediatric patients ≥12 years old
- Existing: heterozygous familial hypercholesterolemia in adult patients
- New: invasive aspergillosis in pediatric patients ≥2 years old
- Existing: invasive aspergillosis in pediatric patients ≥13 years old
- New: supraventricular tachycardia in pediatric patients
- Existing: supraventricular tachycardia in adult patients
- New: narcolepsy in pediatric patients with cataplexy ≥6 years old
- Existing: narcolepsy in pediatric patients with excessive daytime sleepiness ≥6 years old
- Read more: Wakix now approved for cataplexy in pediatric patients with narcolepsy
Formulation Updates
- Added oral solution form: 0.2 mg per mL
First-time Generic
- Indications: moderate-severe acute pain in adult and pediatric patients ≥6 years old
- Equivalent brand: Nucynta